# A Study of ARQ 197 in Combination With Erlotinib

> **NCT01251796** · PHASE1 · COMPLETED · sponsor: **Kyowa Kirin Co., Ltd.** · enrollment: 9 (actual)

## Conditions studied

- Advanced/Recurrent Non-small-cell Lung Cancer

## Interventions

- **DRUG:** ARQ 197 and Erlotinib

## Key facts

- **NCT ID:** NCT01251796
- **Lead sponsor:** Kyowa Kirin Co., Ltd.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2010-12
- **Primary completion:** 2012-11
- **Final completion:** 2012-11
- **Target enrollment:** 9 (ACTUAL)
- **Last updated:** 2017-03-15


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01251796

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01251796, "A Study of ARQ 197 in Combination With Erlotinib". Retrieved via AI Analytics 2026-06-03 from https://api.ai-analytics.org/clinical/NCT01251796. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*